

Lab Utilization Committee Executive Summary 2023

I. Purpose and Composition

- a. Subcommittee of Utilization Management Committee
- b. Oversight of all Clinical Laboratory Testing at MUHC
- c. Reports to Utilization Management and ECOMS
- d. Provides guidance to Lab Utilization Working Committee (LUWC) which implements new testing
- e. Aligns with Contracting and Legal Services
- f. Membership and participation
 - i. Core committee members
 - 1. Detlef Ritter, MD Co-Chair
 - 2. Clayton Butcher, MD Co-Chair
 - 3. Matthew Smith, MD
 - 4. Kevin Clary, MD
 - 5. Brad Myers, PharmD
 - 6. Yezaz Ghouri, MD
 - 7. Amruta Padhye, MD
 - 8. Christian Rojas-Moreno, MD
 - ii. Ancillary committee members
 - 1. Laura Hesemann, MD
 - 2. Robert Pierce, MD
 - 3. Bernie Eskridge, MD
 - iii. Project Managers
 - 1. Kayla Smith
 - 2. Tracy Hall

II. Meetings

a. Conducted monthly meetings (10, did not meet in March and December)

III. Transparency and Accountability

- a. Committee artifacts are available in Teams folder: <u>Lab Utilization Committee Ogrp</u>
 - i. Agendas, Minutes, request documentation, committee artifacts
 - ii. Contact Kayla Smith for access (kayla.m.smith@health.missouri.edu)
- b. All testing information and turnaround expectations are accessible at <u>https://muhealth.testcatalog.org/</u>



IV. Reference Laboratories

- a. All new reference laboratory requests are reviewed by the Lab Utilization Committee and the LUWC
 - i. Status as of December 2023
 - 1. Authorized reference labs: 37
 - 2. <u>https://muhealth.testcatalog.org/show/RLTestRef</u>
- b. Application process for new reference lab requires the following
 - i. Application by attending provider who must be credentialed by MUHC
 - 1. Outside reference lab sales representatives do not qualify
 - ii. Clinical guidelines as established by the LUC

Request clinical guidelines:
 Benefit: impact, new way to improve care (does it replace a currently approved test?)
Risk: Potential harm to patient or institution
Extent and quality of peer-reviewed data
Whether specific test is incorporated into National Guidelines

- Whether specific test is incorporated into National Gu
 Additional cost to patient or institution
- Additional cost to patient or instit
 Other information as needed
- iii. In-person presentation by credentialed attending provider
- iv. Short discussion

c. Requests reviewed in 2023

i. 11 applications received; 1 application retracted with 10 approved

Test Requested	Rendering Laboratory	Requesting Physician
Pancreatic Molecular Markers	Interpace Diagnostics	Dr. Bukeirat (GI)
Albumin ISH	ProPath	Dr. Rao (Pathology)
Unity Screen	BillionToOne	Dr. Guinn (MFM)
Signatera	Natera	Dr. Hirner (Dermatology)
FoundationOne Tracker	Foundation Medicine	Dr. Hildebrandt (Hem/Onc)
AGVHD	Eurofins/Viracor	Dr. Hildebrandt (Hem/Onc)
Afirma Gene Expression Classifier	Veracyte	Dr. Manrique (Endocrinology)
RightMed Pharmacogenomics	OneOme	Dr. Black (Thompson Center)
NAVDX	Vareris	Dr. Biedermann (Rad. Oncology)
L-Asparginase	Granger Genetics	Dr. Bach (Hem/Onc)

d. Reference labs discontinued in 2023

Test	Department	Physician
Exagen DGS	Rheumatology	Dr. Siva
Vectra	Rheumatology	Dr. Siva
Trugraf	Nephrology	Dr. Yerram
First Screen (LabCorps)	ObGyn	

V. MU Policy Reviews and Guidance Completed

- a. Laboratory Pre-analytical specimen collection and processing (guideline)
 - i. Test order authorizations by outside providers (MD/DO/Nurse Practitioners/PA)
- b. Laboratory Reporting critical values and significant findings (policy)
 - i. Critical lab result communications for outside providers
- c. Utilization review Laboratory genetic testing policy

VI. Duplicate Order Alerts – Dr. Robert Pierce, Director of Clinical Decision Support

- a. Reviewed and approved, in conjunction with the Clinical Decision Support Committee, inpatient and outpatient duplicate order alert settings (minimum retesting intervals) for 35 different commonly ordered labs.
- b. Reviewed post-implementation alert data including override rates
- c. Reviewed post-implementation lab completion data and approved modifications of alert business logic to minimize unnecessary alerting.
- d. Future work/plans/goals:
 - i. Audit feedback
 - ii. Dashboard data/visualizations
 - iii. Expansion of order alerts to other tests

Alert and Override Rates

These tables show 4 weeks of alert rates, overrides, and override rates

Inpatient			
Test	Count of alerts	Count of overrides	Override rate
Grand Total	1670	873	52.28%
PTT	330	147	44.55%
Lactate Dehydrogenase	266	232	87.22%
Hemoglobin A1C	223	26	11.66%
Thyroid Stimulating Hormone 3rd Generati	208	90	43.27%
Lipid Profile	85	21	24.71%
Lactic Acid	72	41	56.94%
C Reactive Protein Quantitative	70	48	68.57%
Ferritin Level	66	43	65.15%
Vitamin B12 Level	53	22	41.51%
Triglycerides	49	43	87.76%
Procalcitonin (PCT)	46	30	65.22%
Vitamin D Level	33	18	54.55%
Erythrocyte Sedimentation Rate	32	15	46.88%
Free Thyroxine	31	20	64.52%
Iron Level and TIBC	30	21	70.00%
Folate Level	27	15	55.56%
Bilirubin Total, Blood	19	17	89.47%
Bilirubin Direct	7	6	85.71%
GGT	5	4	80.00%
Prostate Specific Antigen	3	2	66.67%
PSA Screen	3	3	100.00%
T3 Free	3	3	100.00%
T4	3	3	100.00%
Alpha Fetoprotein (AFP)	2	2	100.00%
Anti-Neutrophil Cytoplasmic Antibodies w	1	0	0.00%
Carbamazepine Level	1	1	100.00%
Iron Level	1	0	0.00%
Total IgE Serum	1	0	0.00%

Outpatient			
Test	Count of alerts	Count of overrides	Override rate
Grand Total	3745	3025	80.77%
Thyroid Stimulating Hormone 3rd Generati	591	472	79.86%
Vitamin D Level	451	361	80.04%
Lipid Profile	424	326	76.89%
Ferritin Level	403	346	85.86%
Hemoglobin A1C	367	252	68.66%
PSA Screen	296	253	85.47%
Prostate Specific Antigen	279	254	91.04%
Vitamin B12 Level	221	175	79.19%
Free Thyroxine	119	99	83.19%
Iron Level and TIBC	108	82	75.93%
Lactate Dehydrogenase	84	72	85.71%
C Reactive Protein Quantitative	55	47	85.45%
CA 125	52	49	94.23%
Folate Level	45	32	71.11%
T3 Free	42	32	76.19%
Vitamin D 25 Hydroxy	41	34	82.93%
Alpha Fetoprotein (AFP)	30	24	80.00%
Erythrocyte Sedimentation Rate	23	18	78.26%
Ca 19-9	21	18	85.71%
PTT	14	9	64.29%
Carbamazepine Level	10	10	100.00%
AFP, Tumor Marker	8	8	100.00%
Iron Level	8	7	87.50%
Triglycerides	8	8	100.00%
C Reactive Protein HS	7	7	100.00%
T4	7	5	71.43%
GGT	6	4	66.67%
Insulin-Like Growth Factor 1 (IGF1), LC-	6	5	83.33%
Total IgE Serum	6	3	50.00%
Bilirubin Total, Blood	4	4	100.00%
CA, 15-3	3	3	100.00%
Anti-Neutrophil Cytoplasmic Antibodies w	1	1	100.00%
Bilirubin Direct	1	1	100.00%
CA 15-3-Mayo	1	1	100.00%
CA, 125	1	1	100.00%
CA, 19-9	1	1	100.00%
Insulin-Like Growth Factor-1, LC-MS, Ser	1	1	100.00%

Test Performance

This table shows the **top ten inpatient and outpatient tests** with implemented duplicate order alerts. Shown is the number of tests **performed per week** pre- and post-implementation; annualized tests avoided and estimated annual savings.

		Inpatient		Outpatient		
	Pre	Post	Tests avoided/year	Pre	Post	Tests avoided/year
250H Vit D				8.63	8.41	11.44
HGB A1c	2.08	1.56	27.04	0.52	0.45	3.64
Vit B12	13.17	7.29	305.76	8.74	7.42	68.64
Folic acid						
Lipid panel	4.09	1.58	130.52	1.64	1.4	12.48
CRP	12.2	8.2	208			
Iron/TIBC				3.75	3.92	-8.84
Ferritin	19.8	15.97	199.16	11.91	12.32	-21.32
Procalcitonin	13.97	9.54	230.36			
TSH	11.23	5.66	289.64	2.16	2.34	-9.36
fT4				3.62	3.86	-12.48
РТТ	20.84	19.23	83.72			
Lactate dehydrogenase	53.95	59.32	-279.24	20.12	20.37	-13
Lactic acid	24.8	22.95	96.2			
PSA screen				9.68	2.8	357.76
Total			1291.16			388.96

PowerBI Lab Utilization Dashboard - Under development



VII. Genetic Testing

- a. Lab-driven genetic testing guidance established:
 - i. Establishment of laboratory genetic counselor role.
 - 1. Filled by Caleb A. Heid, MS, CGC
 - ii. Joined Patient-Centered Laboratory Utilization Guidance Services (PLUGS) group
 - 1. Offers recommendations on lab stewardship and utilization management
 - iii. Implemented Utilization Management for Genetic/Molecular Testing
 - 1. Laboratory genetic counseling review for all orders that utilize a molecular CPT code
 - 2. Initiation of prior-authorization and determination of medical necessity
 - 3. Creation of Genetic Testing PowerPlan to help review cases

Genetic testing PowerPlan

Clinicians will now use the Genetic Testing PowerPlan to place orders for various genetic tests

1. Search for	Search: Genetic Testing	Advanced Options 🗸 Type: 🛅 Prescriptions	v
Genetic Testing	🝙 🖆 👷 🚥 🐚 Folder:	Search within: All	~
PowerPlan in	Genetic Testing	Note the love adapt infe	meeting displayed according
PowerOrders	Amniotic Fluid Culture for Genetic Te	-	rmation displayed regarding
A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Routine collect, Amniotic Fluid, N		linicians are encouraged to ant information regarding the
Genetic Testing (Initiated Pending)	t Status		enetic test being ordered.
() IMPORTA	MT: Prior-authorization requires DETAILED information • Please list ALL relevant symptoms. Failure	1 abo	Д.
	 If placing a custom order, please specify i Please note that salva/buccal samples are one of these two labs. 	n the order comments the necessary sample type; failure e only available for tests listed on the GeneDX & Invitae te	enail and high out-of-pocket cost for your patient. to specify may result in an incorrect sample being collected. st catalogs; please confirm that your desired test is available at
	 The rendering laboratory may or may not Please specify the expected discharge date 	change depending on the patient's insurance; if a specifi te in the comments for all in-patient orders.	c lab is necessary, specify in the order comments.
	If you are unable to find a specific test and/or would be umhsmuhcgeneticco1@umsystem.edu, (573) 882 GeneDx test catalog	3. Complete the required field	te indicated by
🗹 🛛 😵 🗖 Genetic Te		oold lettering, an asterisk, and	
4 🛛 🏀 🛇 💠 Add to Phase * 🛕 Che		enetic mg and select	
🛛 🙁 🔂 Genetic Te	modify to comp	blete the order details.	y panel on Blood, Frequent illness., Parental history of rhess
م ا			~
Details for Genetic Testin B [®] Details B [®] Order Comments	•		
+ Add D MO	p onse oceans (a) onequives		
Available Diagnoses			
· I · Encounter for at	her screening for genetic and chromosomal anomalies (Z13.79)		Pending: Future visit 💌
a we			
Collection Da	4 Click the Diagnosis tab t	o confirm that the default Enco	ounter for other screening for
Other Genetic Te	s U	nomalies diagnosis is selected	•
Other Specim		"Family History:	
"Previous Diagnostic		*Differential Diagnosis:	
"How will this test impact medical mana	gement:	*Collection Priority: Routine	
	e Collect: Yes 💿 No	ABN Status:	~
ABN	l Reason:		
Dix Table Orders For Cosignature Or	Inders For Nurse Review Save as My Favorite		Orders For Signature
2	023 estimated cost savin	gs (based on Medicare	Pricing Guide)
	- Direct Pat	ient savings	\$37,830.16
	- Opportuni	ities*	\$495,732.65
	- Institution	al savings	\$578,839.41
		total savings	\$1,112,102.22
*т	he University of Missouri has a	Ũ	
	mbursement was denied due to 1	1 2 1	1 0
	at was saved by completing prior	1	1

VIII. Lab Utilization Working Committee (LUWC)

- a. Initially established alongside LUC to integrate logistical, financial, and IT aspects of all LUC approved tests.
 - i. Involves Supervisors, Managers of all areas of Pathology, Director of Supply Chain and Pathologists.
 - ii. Created 4 Tier flowchart and SOP for area responsibilities and requirements for LUC approvals

Responsibility	Tier 1	Tier 2	Tier3	Tier 4
Placing RL Test Investigation	N/A	Clinician	N/A	N/A
Placing Order	Clinician	Pathology	Clinician	Clinician
Paperwork	Clinician	Clinician	Clinician	Pathology
Result Documentation	Clinician	Pathology	Pathology	Pathology
Kit Storage	Clinician	Clinician	Pathology	Pathology
Sample Collection	Clinician	Pathology	Pathology	Pathology
Sample Send-Out	Clinician	Pathology	Pathology	Pathology

- b. LUWC has now grown to collaborate with all Pathology departments on various aspects of pathology testing
 - i. Bi-Weekly meeting
 - ii. MU Test Catalog updates
 - iii. Reference Lab change requests
 - iv. Multi-Disciplinary changes or implementation of testing
 - v. Contracting/Legal/Supply Chain collaboration
 - 1. Attendees
 - a. Dr. Ritter
 - b. Dr. Walker
 - c. Jason Sawyer
 - d. Cody Buxton
 - e. Christine Martin
 - f. Caitlin Lenon-Davis
 - g. Shanon Larson-Kosnopfal
 - h. Amanda Ramsey
 - i. Cisco Saenz
 - j. Susan Poole
 - k. Caleb Heid
 - 1. Tammy Dowdell
 - m. Jordan Richards
 - n. Michael Athey
 - o. Karen Rugg
 - p. Rob Hollinger
- c. Accomplishments of 2023
 - i. Successful reduction in phlebotomy patient wait time due to elimination of Lab Assistant guess work
 - ii. Reduction of surprise billing to Laboratory Budget or Patient
 - iii. Creation of 3rd Party orders in PowerChart and full interphases built to improve order and billing accuracy while reducing resulting wait times